bisorcic
{{Short description|Liver-protective and stimulant drug}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| drug_name =
| image = Bisorcic.svg
| width = 100px
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| dependency_liability =
| addiction_liability =
| routes_of_administration = Oral
| class = Hepatoprotective agent; Psychostimulant
| ATC_prefix =
| ATC_suffix =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 39825-23-5
| CAS_supplemental =
| PubChem = 65977
| IUPHAR_ligand =
| DrugBank =
| ChemSpiderID = 59375
| UNII = 3V77J79MIF
| KEGG =
| ChEBI = 133217
| ChEMBL = 3989425
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = N2,N5-Diacetyl-L-ornithine; N2,N5-Diacetylornithine; Nα,Nδ-Diacetylornithine
| IUPAC_name = (2S)-2,5-diacetamidopentanoic acid
| C=9 | H=16 | N=2 | O=4
| SMILES = CC(=O)NCCC[C@@H](C(=O)O)NC(=O)C
| StdInChI = 1S/C9H16N2O4/c1-6(12)10-5-3-4-8(9(14)15)11-7(2)13/h8H,3-5H2,1-2H3,(H,10,12)(H,11,13)(H,14,15)/t8-/m0/s1
| StdInChIKey = XUYANFPPYJSBPU-QMMMGPOBSA-N
}}
Bisorcic ({{Abbrlink|INN|International Nonproprietary Name}}), also known as N2,N5-diacetyl-L-ornithine, is a drug described as a hepatoprotective agent and "psychostimulant" which has been used in France in the treatment of asthenia.{{cite book | vauthors = Elks J | title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies | publisher=Springer US | year=2014 | isbn=978-1-4757-2085-3 | url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA906 | access-date=28 September 2024 | page=906 | quote = Nα,Nδ-Di-Ac: [39825-23-5]. N2,N5-Diacetylornithine, 9Cl. Bisorcic, INN. 69H16N2O4. M 216,236. Hepatoprotective agent, psychostimulant. [...] Ger. Pat., 2 219 874, (1973); CA, 78, 98010t (Bisorcic).}}{{cite book | vauthors = Buckingham J | title=Dictionary of Natural Products | issue = Supplement 1 | publisher=CRC Press | year=2020 | isbn=978-1-000-15302-6 | url=https://books.google.com/books?id=YJgFEAAAQBAJ&pg=PA356 | access-date=28 September 2024 | page=356}}{{cite book | vauthors = Blunt JW, Munro MH | title=Dictionary of Marine Natural Products with CD-ROM | publisher=CRC Press | year=2007 | isbn=978-0-8493-8217-8 | url=https://books.google.com/books?id=w1bLBQAAQBAJ&pg=PA522 | access-date=28 September 2024 | page=522}}{{cite book | vauthors = Negwer M | title=Organic-chemical Drugs and Their Synonyms: (an International Survey) | publisher=Akademie Verlag | year=1994 | isbn=978-3-05-500156-7 | url=https://books.google.com/books?id=1ghtAAAAMAAJ | access-date=28 September 2024 | page=359 | quote=6220. 39825-23-5 CI CI -NH2 N C10H10CI2N2O2 51 230-28-5. N2,N5-Diacetyl-L-ornithine. R see also no. 3704. S Bisorcic**. U Psychostimulant.}}{{cite book | vauthors = Schlesser JL | title=Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved for Use Outside the U. S. | publisher=Gale Research; Derwent Publications Ltd. | year=1990 | isbn=978-0-8103-7177-4 | url=https://books.google.com/books?id=2x1tAAAAMAAJ | access-date=28 September 2024 | page=24 | quote = 109 BISORCIC. Countries Where Available and Release Dates: France (1987). Brand Names and Manufacturers: Astyl-Gallier (France). Drug Action: Psychostimulant. Indications/Usage: Asthenia. How Supplied: 200 mg capsules. Dosage: 4 capsules daily. Not recommended in children. Contraindications: Epilepsy.}} It is the N2,N5-diacetylated derivative of the amino acid L-ornithine.{{cite web | title=Bisorcic | work = PubChem | publisher = U.S. National Library of Medicine | url=https://pubchem.ncbi.nlm.nih.gov/compound/65977 | access-date=28 September 2024}}
Bisorcic was first described in the literature in 1973 in a German patent. The {{Abbrlink|INN|International Nonproprietary Name}} was designated around 1975.{{cite journal | title = Proposed International Nonproprietary Names (Prop. INN): List 34. International Nonproprietary Names for Pharmaceutical Substances. | journal = Supplement to WHO Chronicle | date = 1975 | volume = 29 | issue = 9 | url=https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl34.pdf | access-date=28 September 2024}} The drug was marketed in France by Astyl-Gallier in 1987. It was provided in the form of 200{{nbsp}}mg oral capsules and four capsules were taken daily.
L-Ornithine, as the combination drug L-ornithine L-aspartate (LOLA), has been used in the treatment of hepatic encephalopathy and cirrhosis and is likewise described as hepatoprotective.{{cite journal | vauthors = Kircheis G, Lüth S | title = Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy | journal = Drugs | volume = 79 | issue = Suppl 1 | pages = 23–29 | date = February 2019 | pmid = 30706424 | pmc = 6416235 | doi = 10.1007/s40265-018-1023-2 }}{{cite journal | vauthors = Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY | title = L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis | journal = The Cochrane Database of Systematic Reviews | volume = 5 | issue = 5 | pages = CD012410 | date = May 2018 | pmid = 29762873 | pmc = 6494563 | doi = 10.1002/14651858.CD012410.pub2 }} It is thought to work by participating in the urea cycle and lowering ammonia levels.
References
{{Reflist}}
{{Stimulants}}